99精品久久久久中文字幕,国产va免费精品

(±)-Lisofylline

NMR下載 COA and HPLC MSDS下載
names：
(±)-Lisofylline, Anti-inflammatory agent
CAS號：
6493-06-7
MDL Number：
MF(分子式)： C13H20N4O3 MW(分子量)： 280.33
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	(±)-Lisofylline(6493-06-7);Lisofylline (raceimic)
英文別名	(±)-Lisofylline, Anti-inflammatory agent(6493-06-7);LSF;Lisofylline;CT 1501R;ProTec;
CAS號	6493-06-7
Inchi	InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3
InchiKey	NSMXQKNUPPXBRG-UHFFFAOYSA-N
分子式 Formula	C13H20N4O3
分子量 Molecular Weight	280.33
溶解度Solubility
性狀	Solid powder
儲藏條件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

產(chǎn)品說明	Lisofylline (raceimic)(CAS:6493-06-7):僅限應用于工業(yè)或者科學研究過程中非醫(yī)療目的，不應用于人類或動物的臨床診斷以及治過程療，該產(chǎn)品非藥用，非食用。
Introduction	Lisofylline, also known as LSF, improves cellular mitochondrial function and blocks interleukin-12 (IL-12) signaling and STAT-4 activation in target cells and tissues. IL-12 and STAT-4 activation are important pathways linked to inflammation and autoimmune damage to insulin producing cells. Therefore, LSF and related analogs could provide a new therapeutic approach to prevent or reverse type 1 diabetes.
Application1
Application2
Application3

警示圖
危險性	Warning
危險性警示
安全聲明
安全防護
備注

[1]Jung HS, Kaplan LJ, Park PK. Reviewing the studies of the National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network: outcomes and clinical findings. Curr Probl Surg. 2013 Oct;50(10):451-62. doi: 10.1067/j.cpsurg.2013.08.009. Review. PubMed PMID: 24156843.

[2]Jain R, DalNogare A. Pharmacological therapy for acute respiratory distress syndrome. Mayo Clin Proc. 2006 Feb;81(2):205-12. Review. PubMed PMID: 16471076.

[3] Yang Z, Chen M, Nadler JL. Lisofylline: a potential lead for the treatment of diabetes. Biochem Pharmacol. 2005 Jan 1;69(1):1-5. Review. PubMed PMID: 15588708.

[4] Wiedemann HP, Arroliga AC, Komara JJ Jr. Emerging systemic pharmacologic approaches in acute respiratory distress syndrome. Respir Care Clin N Am. 2003 Dec;9(4):419-35. Review. PubMed PMID: 14984064.

[5] Bhandari V. Developmental differences in the role of interleukins in hyperoxic lung injury in animal models. Front Biosci. 2002 Jul 1;7:d1624-33. Epub 2002 Jul 1. Review. PubMed PMID: 12108429.

6: Sturm A, Dignass AU. Modulation of gastrointestinal wound repair and inflammation by phospholipids. Biochim Biophys Acta. 2002 May 23;1582(1-3):282-8. Review. PubMed PMID: 12069839.7: Bright JJ, Sriram S. Immunotherapy of inflammatory demyelinating diseases of the central nervous system. Immunol Res. 2001;23(2-3):245-52. Review. PubMed PMID: 11444389.8: Nemunaitis J. Recombinant hematopoietic growth factors in bone marrow transplantation. Cancer Treat Res. 1995;7

對不起，暫無產(chǎn)品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開